
    
      The objective is to follow participants receiving cluster of differentiation (CD) 20 /
      cluster of differentiation (CD) 19 lentiviral modified CAR-T cells (CAR-20/19-T cells) from
      years 2 to 15 post-treatment for persistence of CAR-T cells, development of secondary
      malignancies, or other medical complications.
    
  